NEW YORK, Jan. 15, 2020 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from dermatological
indications ranging from atopic dermatitis, psoriasis and acne
along with gene therapy treatment for asthmatics, announced today
it has exercised its option to take an exclusive license for
patents owned by the George Washington
University (GW). Hoth used the option period to
evaluate GW's unique Substance P receptor blocker (Aprepitant) that
inhibited cutaneous and other neurogenic inflammation side effects
that cancer patients suffer during treatment with anticancer
drugs. The exercise of the option agreement allows for Hoth to
negotiate an exclusive patent license agreement. The option
agreement included pre-negotiated business terms for the exclusive
patent license, so Hoth anticipates finalizing the license this
month.
In June of 2019, Hoth entered into a sponsored research
agreement with GW to explore the potential use of
Aprepitant in different forms.
Mr. Robb Knie, Chief Executive Officer of Hoth, commented,
"Our research collaboration with GW has yielded positive
preliminary results. Our next step will be to plan for the
quickest pathway to help patients suffering from adverse events,
often so severe that they impair the patient's compliance with the
anticancer treatment and even cause its discontinuation.
Management looks forward to sharing the preclinical results of our
unique formulation of this topical therapeutic upon its completion
later this year."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on
developing new generation therapies for dermatological disorders.
HOTH's pipeline has the potential to improve the quality of life
for patients suffering from indications including atopic
dermatitis, chronic wounds, psoriasis, and acne. HOTH has the
exclusive worldwide rights to BioLexa, the company's proprietary
lead drug candidate topical platform that uniquely combines two FDA
approved compounds to fight bacterial infections across multiple
indications. HOTH is preparing to launch its clinical trial for the
treatment of adolescent subjects, 2-17 years of age, with mild to
moderate atopic dermatitis during 2020. To learn more, please
visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain. Hoth may not realize its
expectations, and its beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contacts
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
(212) 896-1254 / (212) 682-6300
Hoth@kcsa.com
SOURCE Hoth Therapeutics, Inc.